Home/ Supplements/ Niacin/ Glucose Tolerance

Glucose Tolerance

product on market Capsule Allergy Research Group Safety: 92/100
92/100

This product looks safe

  • Niacin: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)
  • 60% of ingredients have research evidence
C Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Chromium and Vitamin B6 are supported by moderate evidence for aiding glucose metabolism and insulin sensitivity. Niacin and L-glutathione provide antioxidant support, while guar gum may influence glycemic response. Overall, the evidence coverage for this specific combination is limited.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Niacin: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)

Label

Product Label

Label for Glucose Tolerance
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Capsule(s)
Serving Size
90
Servings
Other Combinations
Product Type
60%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

50 mg (250% DV)
Exceeds UL by 1.4× (UL: 35 mg) 196 studies (A:5, B:63)
20 mg (1000% DV)
15.4× RDA — above typical dose (UL: 100 mg) 114 studies (A:3, B:35)
250 mcg (208% DV)
7.1× RDA — above typical dose 199 studies (A:1, B:55)
L-Glutathione
2.5 mg
Guar Gum
450 mg

Other Ingredients

Hydroxypropyl Methylcellulose Microcrystalline Cellulose Silicon Dioxide Magnesium Stearate
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Directions for Use

Suggested Use As a dietary supplement, 1 capsule daily with a meal and 8 ounces of water, or as directed by a healthcare practitioner.

Additional Information

Variations in product color may occur.

Keep in a cool, dry place, tightly capped.

Rev. 004

Metadata

Product Details

UPC / SKU7 13947 71900 2
DSLD Entry Date2015-12-23
Product TypeOther Combinations
FormCapsule
DSLD ID54485
Data Updated2026-04-11
Research

Research Evidence

241
Research Sources
55
Avg Quality
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013 PubMed DOI
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014 PubMed DOI
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024 PubMed DOI
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010 PubMed DOI
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010 PubMed DOI
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019 PubMed DOI
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016 PubMed DOI
View all evidence for Niacin →
Compare

Similar Products

View all Niacin products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.